Talis Biomedical Corporation

Equities

TLIS

US87424L2079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
8.75 USD -1.41% Intraday chart for Talis Biomedical Corporation -4.89% +17.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading DJ
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Talis Biomedical Announces Exploration of Strategic Alternatives CI
Talis Biomedical Corporation Announces Resignation of Melissa Gilliam from its Board of Directors, as Member of Nominating and Corporate Governance Committee and as Member and Co-Chairperson of Science, Technology and Clinical Affairs Committee CI
BTIG Adjusts Talis Biomedical's Price Target to $5 From $5.25, Keeps Sell Rating MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Talis Biomedical Corporation, Q2 2023 Earnings Call, Aug 10, 2023
Talis Biomedical Corporation Announces Resignation of Andrew A. Lukowiak as President and Chief Scientific Officer CI
Talis Biomedical Corporation Announces New Data Supporting the Development of Its Planned CT/NG/TV and Vinal Infections Panels CI
Talis Biomedical Appoints Former Roche Molecular CEO Heiner Dreismann to Board of Directors CI
Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Transcript : Talis Biomedical Corporation, Q1 2023 Earnings Call, May 11, 2023
Talis Biomedical Corporation Appoints Kimberly Popovits as Lead Independent Director CI
Talis Biomedical Corporation Announces Executive Changes CI
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Reports Q4 Revenue $0.3M MT
North American Morning Briefing : Stock Futures -2- DJ
Talis Biomedical Corporation Announces Resignation of Felix Baker from the Board of Directors CI
Talis Biomedical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Posts Q3 Revenue $796,000 MT
Talis Biomedical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Transcript : Talis Biomedical Corporation, Q2 2022 Earnings Call, Aug 02, 2022
Earnings Flash (TLIS) TALIS BIOMEDICAL CORPORATION Posts Q2 Revenue $0.6M MT
Talis Biomedical Corporation(NasdaqGM:TLIS) dropped from S&P Global BMI Index CI
Talis Biomedical Corporation Announces Resignation of Raymond Cheong from Board of Directors CI
Talis Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chart Talis Biomedical Corporation
More charts
Talis Biomedical Corporation is engaged in transforming diagnostic testing by developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions at the point of care. The Company is engaged in developing the Talis One system, a cloud-enabled molecular diagnostic platform. The Talis One system consists of compact instrument, single-use test cartridges and software that is designed to support a central cloud database, which work together and are designed to provide central laboratory levels of accuracy and be operated by an untrained user. It is also focused on developing Talis One assay kits for respiratory infections, and infections related to women's health and sexually transmitted infections (STIs). It is also developing influenza A and influenza B tests to be included as part of a respiratory panel with its COVID-19 assay (Respiratory Panel), as well as exploring adding a respiratory syncytial virus (RSV) test.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock Talis Biomedical Corporation - Nasdaq
  4. News Talis Biomedical Corporation
  5. Talis Biomedical : JPMorgan Downgrades Talis Biomedical to Underweight From Neutral, Cuts Price Target to $7 from $10